CMS Administrator McClellan Proposes Medicare-Based Prescription Drug Monitoring System
Main Category: Medicare / Medicaid / SCHIPArticle Date: 07 Jun 2005 - 0:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
CMS Administrator Mark McClellan has proposed using billing data and health care information collected from Medicare beneficiaries to create a more effective post-market surveillance system for prescription drugs, the... Los Angeles Times reports. He suggested collecting adverse event information from Medicare beneficiaries who enroll in the new prescription drug benefit, which begins Jan. 1, 2006. Officials would use billing data from the benefit and combine it with health care information already collected by Medicare when beneficiaries submit claims. A computer system then could cross-reference the information and detect problems with medications. FDA's current surveillance network uses voluntary submission of reports to the Adverse Event Reporting System database. The system collects about 400,000 reports of adverse events annually but detects only 10% of serious drug reactions -- a figure most experts believe "only scratches the surface," according to the Times. While the system can detect rarer side effects effectively, it is not reliable in identifying whether a drug caused a common medical problem, such as a heart attack, or risks that emerge several years after a drug has launched. In addition, the system does not provide information on how many people are taking each drug, which is important for calculating the prevalence of any problem.
McClellan Comments
"The electronic systems we would need are already going to be in place," McClellan said, adding, "We need them for Medicare to determine what to pay. The incremental cost of doing this is very low ... well under $10 million a year." McClellan said beneficiaries' personal information would be protected, and federal officials would have a more effective and faster system for detecting problems. He added, "In an era when we should be depending on electronic systems, it should not take five years and millions of patients before we get to a potential problem." McClellan also said a Medicare monitoring system could help determine which drug treatments are most cost-effective. According to the Times, Sens. Chuck Grassley (R-Iowa) and Max Baucus (D-Mont.) are considering legislation that would allow Medicare to establish such a monitoring system.
FDA Response
An FDA spokesperson said the agency is "exploring [the] possibility" of creating a Medicare-based drug monitoring system but added that "[i]t really is too early." Participants of a recent FDA drug safety advisory committee meeting discussed ways to improve the drug monitoring system, including a Medicare-based one. However, after two days of deliberations, "[n]o one at [FDA] was willing to say, 'OK, this is what we would like to do,'" panel member Curt Furberg, an epidemiologist at Wake Forest University, said. Panel Chair Peter Gross, chair of the Department of Internal Medicine at Hackensack University Medical Center, said he believes the Medicare proposal is a good idea but added that he did not "get the sense that (the FDA officials) were latching on to it."
Other Reaction
Raymond Woosley, vice president of the University of Arizona Health Sciences Center, said, "I think it's a huge opportunity. We're going to be spending billions of dollars on medications for the elderly, and we're calling it a 'benefit.' But if we don't have a way to monitor outcomes from the use of these medicines, it may not be a benefit." Woosley said he believes FDA ultimately will support such a system. However, Henri Manasse, a spokesperson for the American Society of Health-System Pharmacists, said, "Some people may be afraid of this data. If this system were to detect a lot of bad prescribing related to the marketing practices of the pharmaceutical industry, the industry would not be very happy. So there could be some political downside, but medically it could help deliver the best care for the available money" (Alonso-Zaldivar, Los Angeles Times, 6/5).
CMS
"Reprinted with permission from kaisernetwork.org kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our medicare / medicaid / schip section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/25730.php>
APA
http://www.medicalnewstoday.com/releases/25730.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




